Braveheart Bio: Funding, Investors & Team (Sep 2026)
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
Braveheart Bio has raised $185M across 1 funding round on record, the most recent a Series A of $185M announced in Nov 2025.
That round is above the $15M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Braveheart Bio Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Braveheart Bio Funding Rounds
Braveheart Bio Founders and Leadership Team
Contact details for the Braveheart Bio team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Braveheart Bio Funding Compared to Other Biotechnology Startups
Braveheart Bio's latest round of $185M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Biotechnology Startups Like Braveheart Bio
Companies Similar to Braveheart Bio
Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific…
Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading…
Ventuno Biotech is a biotech company that is developing innovative cancer therapies.
Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures…
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and…
Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies
Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe…
Curadel Surgical Innovations oversees the complete process of Curadel's FLARE contrast agents for…
Treating the seeds of cancer
Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.
Braveheart Bio Funding FAQs
What does Braveheart Bio do?
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
How much funding has Braveheart Bio raised?
Braveheart Bio has raised $185M across 1 round on record. The most recent is a Series A of $185M announced in Nov 2025.
When did Braveheart Bio last raise funding?
Braveheart Bio's most recent funding round on record is a Series A of $185M, announced in Nov 2025.
How many employees does Braveheart Bio have?
Braveheart Bio is in the 1-10 employee band.
How does Braveheart Bio's funding compare to other Biotechnology startups?
Braveheart Bio's latest round of $185M is above the $15M median round size for Biotechnology companies on FundedIQ across 16 tracked companies over the last two years.
About FundedIQ's Braveheart Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Braveheart Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.